Drugs / MNPR-101-DFO*-89Zr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06337084 | May 2024 → Apr 2026 overdue | colorectal cancer, gastric cancer, lung cancer, malignant pancreatic neoplasm +4 | Monopar Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNPR-101-DFO*-89Zr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06337084 ↗ |
| Modality | Monoclonal antibody | “humanized IgG1 monoclonal antibody” NCT06337084 ↗ |
| Route | Intravenous | “infused intravenously on Day 1” NCT06337084 ↗ |